Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Nektar Therapeutics’s stock clocked out at $0.75, down -3.60% from its previous closing price of $0.78. In other words, the price has decreased by -$3.60 from its previous closing price. On the day, 1.4 million shares were traded. NKTR stock price reached its highest trading level at $0.8 during the session, while it also had its lowest trading level at $0.74.
Ratios:
To gain a deeper understanding of NKTR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.26 and its Current Ratio is at 4.26. In the meantime, Its Debt-to-Equity ratio is 3.20 whereas as Long-Term Debt/Eq ratio is at 2.87.
On March 14, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $6.
On January 08, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on January 08, 2025, with a $4 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 19 ’25 when Zalevsky Jonathan sold 10,300 shares for $1.01 per share. The transaction valued at 10,403 led to the insider holds 316,604 shares of the business.
Wilson Mark Andrew sold 11,040 shares of NKTR for $11,150 on Feb 19 ’25. The Chief Legal Officer now owns 324,292 shares after completing the transaction at $1.01 per share. On Feb 19 ’25, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 23,774 shares for $1.01 each. As a result, the insider received 24,012 and left with 1,086,901 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 139950208 and an Enterprise Value of 79063896. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.42 while its Price-to-Book (P/B) ratio in mrq is 2.30. Its current Enterprise Value per Revenue stands at 0.803 whereas that against EBITDA is -0.63.
Stock Price History:
The Beta on a monthly basis for NKTR is 0.59, which has changed by -0.5454545 over the last 52 weeks, in comparison to a change of 0.09765589 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.43. The 50-Day Moving Average of the stock is 0.44%, while the 200-Day Moving Average is calculated to be -28.13%.
Shares Statistics:
It appears that NKTR traded 2.47M shares on average per day over the past three months and 1717820 shares per day over the past ten days. A total of 185.78M shares are outstanding, with a floating share count of 179.37M. Insiders hold about 3.62% of the company’s shares, while institutions hold 69.04% stake in the company. Shares short for NKTR as of 1744675200 were 8136669 with a Short Ratio of 3.29, compared to 1741910400 on 6947547. Therefore, it implies a Short% of Shares Outstanding of 8136669 and a Short% of Float of 4.5.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Nektar Therapeutics (NKTR) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.17 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.61 and -$0.79 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.76, with 3.0 analysts recommending between -$0.67 and -$0.87.
Revenue Estimates
Based on 8 analysts’ estimates, the company’s revenue will be $63.11M in the next fiscal year. The high estimate is $132.74M and the low estimate is $24M.
